Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All BMS mAbs studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchBMS mAbsBMS mAbs (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities

Focosi, D., Current Topics in Microbiology and Immunology, doi:10.1007/82_2024_268
Aug 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Review of monoclonal antibodies for SARS-CoV-2. Author notes that the omicron variant has reset achievements to date.
Focosi et al., 11 Aug 2024, peer-reviewed, 1 author.
This PaperBMS mAbsAll
{ 'indexed': {'date-parts': [[2024, 8, 11]], 'date-time': '2024-08-11T00:28:19Z', 'timestamp': 1723336099552}, 'publisher-location': 'Berlin, Heidelberg', 'reference-count': 117, 'publisher': 'Springer Berlin Heidelberg', 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2024]]}, 'DOI': '10.1007/82_2024_268', 'type': 'book-chapter', 'created': {'date-parts': [[2024, 8, 10]], 'date-time': '2024-08-10T13:04:12Z', 'timestamp': 1723295052000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities', 'prefix': '10.1007', 'author': [{'given': 'Daniele', 'family': 'Focosi', 'sequence': 'first', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2024, 8, 11]]}, 'reference': [ { 'key': '268_CR1', 'doi-asserted-by': 'publisher', 'unstructured': 'ACTIV-3/TICO LY-CoV555 Study Group (2020) A neutralizing monoclonal ' 'antibody for hospitalized patients with Covid-19. N Engl J Med ' '384(10):905–914. https://doi.org/10.1056/NEJMoa2033130', 'DOI': '10.1056/NEJMoa2033130'}, { 'key': '268_CR2', 'unstructured': 'ACTIV-3: Therapeutics for Inpatients With COVID-19—Full Text ' 'View—ClinicalTrials.gov'}, { 'key': '268_CR3', 'doi-asserted-by': 'publisher', 'unstructured': 'Anderson TS, O’Donoghue A, Mechanic O, Dechen T, Stevens J (2022) ' 'Administration of anti–SARS-CoV-2 monoclonal antibodies after US food ' 'and drug administration deauthorization. JAMA Netw Open 5(8):e2228997-e. ' 'https://doi.org/10.1001/jamanetworkopen.2022.28997', 'DOI': '10.1001/jamanetworkopen.2022.28997'}, { 'key': '268_CR4', 'unstructured': 'AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE ' 'Phase III outpatient treatment trial (2022). Accessed online at ' 'https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/azd7442-phiii-trial-positive-in-covid-outpatients.html ' 'on 22 Feb 2022'}, { 'issue': 'S0085–2538', 'key': '268_CR5', 'doi-asserted-by': 'publisher', 'first-page': '00383', 'DOI': '10.1016/j.kint.2022.05.008', 'volume': '22', 'author': 'I Benotmane', 'year': '2022', 'unstructured': 'Benotmane I, Velay A, Thaunat O, Vargas GG, Olagne J, Fafi-Kremer S et ' 'al (2022) Pre-exposure prophylaxis with Evusheld™ elicits limited ' 'neutralizing activity against the Omicron variant in kidney transplant ' 'patients. Kidney Int 22(S0085–2538):00383. ' 'https://doi.org/10.1016/j.kint.2022.05.008', 'journal-title': 'Kidney Int'}, { 'issue': '7838', 'key': '268_CR6', 'doi-asserted-by': 'publisher', 'first-page': '485', 'DOI': '10.1038/s41586-020-2838-z', 'volume': '588', 'author': 'S Bournazos', 'year': '2020', 'unstructured': 'Bournazos S, Corti D, Virgin HW, Ravetch JV (2020) Fc-optimized ' 'antibodies elicit CD8 immunity to viral respiratory infection. Nature ' '588(7838):485–490. https://doi.org/10.1038/s41586-020-2838-z', 'journal-title': 'Nature'}, { 'key': '268_CR7', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-021-04386-2', 'author': 'E Cameroni', 'year': '2021', 'unstructured': 'Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K et al ' '(2021) Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron ' 'antigenic shift. Nature. https://doi.org/10.1038/s41586-021-04386-2', 'journal-title': 'Nature'}, { 'key': '268_CR8', 'doi-asserted-by': 'publisher', 'unstructured': 'Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A et al (2022) Imprinted ' 'SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. ' 'Nature. https://doi.org/10.1038/s41586-022-05644-7', 'DOI': '10.1038/s41586-022-05644-7'}, { 'key': '268_CR9', 'doi-asserted-by': 'crossref', 'unstructured': 'Casadevall A, Focosi D (2023) SARS-CoV-2 variants resistant to ' 'monoclonal antibodies in immunocompromised patients is a public health ' 'concern. J Clin Invest', 'DOI': '10.1172/JCI168603'}, { 'key': '268_CR10', 'doi-asserted-by': 'publisher', 'unstructured': 'Dalakas MC, Spaeth PJ (2021) The importance of FcRn in ' 'neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, ' 'IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol ' 'Disord. https://doi.org/10.1177/1756286421997381', 'DOI': '10.1177/1756286421997381'}, { 'issue': '9', 'key': '268_CR11', 'doi-asserted-by': 'publisher', 'first-page': '886', 'DOI': '10.1097/inf.0000000000001916', 'volume': '37', 'author': 'JB Domachowske', 'year': '2018', 'unstructured': 'Domachowske JB, Khan AA, Esser MT, Jensen K, Takas T, Villafana T et al ' '(2018) Safety, tolerability and pharmacokinetics of MEDI8897, an ' 'extended half-life single-dose respiratory syncytial virus prefusion ' 'F-targeting monoclonal antibody administered as a single dose to healthy ' 'preterm infants. Pediatr Infect Dis J 37(9):886–892. ' 'https://doi.org/10.1097/inf.0000000000001916', 'journal-title': 'Pediatr Infect Dis J'}, { 'key': '268_CR12', 'doi-asserted-by': 'crossref', 'unstructured': 'Drysdale M, Gibbons DC, Singh M, Rolland C, Lavoie L, Skingsley A et al ' '(2024) Real-world effectiveness of sotrovimab for the treatment of ' 'SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a ' 'systematic literature review. Infection 52:1–17', 'DOI': '10.1007/s15010-023-02098-5'}, { 'key': '268_CR13', 'unstructured': 'ETF statement on the loss of activity of anti-spike protein monoclonal ' 'antibodies due to emerging SARS-CoV-2 variants of concern (2022). 9 ' 'December 2022 EMA/931457/2022. Accessed online at ' 'https://www.ema.europa.eu/en/documents/public-statement/etf-statement-loss-activity-anti-spike-protein-monoclonal-antibodies-due-emerging-sars-cov-2_en.pdf'}, { 'key': '268_CR14', 'unstructured': 'ETF warns that monoclonal antibodies may not be effective against ' 'emerging strains of SARS-CoV-2 (2023). Accessed online at ' 'https://www.ema.europa.eu/en/news/etf-warns-monoclonal-antibodies-may-not-be-effective-against-emerging-strains-sars-cov-2 ' 'on 24 Jan 2023'}, { 'issue': '5', 'key': '268_CR15', 'doi-asserted-by': 'publisher', 'first-page': '658', 'DOI': '10.7326/m22-3428', 'volume': '176', 'author': 'TH Evering', 'year': '2023', 'unstructured': 'Evering TH, Chew KW, Giganti MJ, Moser C, Pinilla M, Wohl DA et al ' '(2023) Safety and efficacy of combination SARS-CoV-2 neutralizing ' 'monoclonal antibodies Amubarvimab plus Romlusevimab in nonhospitalized ' 'patients With COVID-19. Ann Intern Med 176(5):658–666. ' 'https://doi.org/10.7326/m22-3428', 'journal-title': 'Ann Intern Med'}, { 'key': '268_CR16', 'unstructured': 'Fact sheet for healthcare providers: emergency use authorization for ' 'bebtelovimab (2022). Accessed online at ' 'https://www.fda.gov/media/156152/download on 21 Feb 2022'}, { 'key': '268_CR17', 'unstructured': 'FDA (2022) Coronavirus (COVID-19) update: FDA authorizes New monoclonal ' 'antibody for treatment of COVID-19 that retains activity against Omicron ' 'variant. Accessed online at ' 'https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains ' 'on 17 Feb 2022'}, { 'key': '268_CR18', 'unstructured': 'FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region ' '(2022). Accessed online at ' 'https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region ' 'on 1 Dec 2022'}, { 'key': '268_CR19', 'unstructured': 'FDA announces Evusheld is not currently authorized for emergency use in ' 'the U.S. (2023) Accessed online at ' 'https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us ' 'on 3 Feb 2023'}, { 'key': '268_CR20', 'unstructured': 'FDA Statement (2022) Coronavirus (COVID-19) update: FDA limits use of ' 'certain monoclonal antibodies to treat COVID-19 due to the Omicron ' 'variant. ' 'https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron ' 'Accessed 8 June 2023'}, { 'key': '268_CR21', 'unstructured': 'FDA updates Sotrovimab emergency use authorization. March 30, 2022. ' 'https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization ' 'Accessed 9 June 2023'}, { 'key': '268_CR22', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/rmv.2231', 'author': 'D Focosi', 'year': '2021', 'unstructured': 'Focosi D, Maggi F (2021) Neutralising antibody escape of SARS-CoV-2 ' 'spike protein: risk assessment for antibody-based Covid-19 therapeutics ' 'and vaccines. Rev Med Virol. https://doi.org/10.1002/rmv.2231', 'journal-title': 'Rev Med Virol'}, { 'key': '268_CR23', 'doi-asserted-by': 'publisher', 'first-page': '219', 'DOI': '10.2217/fmb-2021-0286', 'volume': '17', 'author': 'D Focosi', 'year': '2022', 'unstructured': 'Focosi D, Maggi F, McConnell S, Casadevall A (2022a) Spike mutations in ' 'SARS-CoV-2 AY sublineages of delta variant of concern: implications for ' 'the future of the pandemic. Future Microbiol 17:219–221. ' 'https://doi.org/10.2217/fmb-2021-0286', 'journal-title': 'Future Microbiol'}, { 'issue': '1', 'key': '268_CR24', 'doi-asserted-by': 'crossref', 'first-page': '29', 'DOI': '10.3390/ijms23010029', 'volume': '23', 'author': 'D Focosi', 'year': '2022', 'unstructured': 'Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A (2022b) ' 'Analysis of immune escape variants from antibody-based therapeutics ' 'against COVID-19: a systematic review. Int J Mol Sci 23(1):29', 'journal-title': 'Int J Mol Sci'}, { 'issue': '11', 'key': '268_CR25', 'doi-asserted-by': 'publisher', 'first-page': '00311', 'DOI': '10.1016/S1473-3099(22)00311-5', 'volume': '22', 'author': 'D Focosi', 'year': '2022', 'unstructured': 'Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M ' '(2022c) Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect ' 'Dis 22(11):00311–00315. https://doi.org/10.1016/S1473-3099(22)00311-5', 'journal-title': 'Lancet Infect Dis'}, { 'issue': '3', 'key': '268_CR26', 'doi-asserted-by': 'crossref', 'first-page': '2264', 'DOI': '10.3390/ijms24032264', 'volume': '24', 'author': 'D Focosi', 'year': '2023', 'unstructured': 'Focosi D, Quiroga R, McConnell S, Johnson MC, Casadevall A (2023a) ' 'Convergent evolution in SARS-CoV-2 Spike creates a variant soup from ' 'which new COVID-19 waves emerge. Int J Mol Sci 24(3):2264', 'journal-title': 'Int J Mol Sci'}, { 'key': '268_CR27', 'doi-asserted-by': 'crossref', 'unstructured': 'Focosi D (2023) A web tool to estimate baaseline anti-Spike monoclonal ' 'antibody efficacy based on regional genomic surveillance. Viruses ' '15(5):1048', 'DOI': '10.3390/v15051048'}, { 'key': '268_CR28', 'doi-asserted-by': 'crossref', 'unstructured': 'Focosi D, Maggi F (2023) Respiratory delivery of passive immunotherapies ' 'for SARS-CoV-2 prophylaxis and therapy. Hum Vaccines Immunotherap 19(2)', 'DOI': '10.1080/21645515.2023.2260040'}, { 'key': '268_CR29', 'doi-asserted-by': 'publisher', 'unstructured': 'Focosi D, Tuccori M (2022) Prescription of anti-spike monoclonal ' 'antibodies in COVID-19 patients with resistant SARS-CoV-2 variants in ' 'Italy. Pathogens (Basel, Switzerland) 11(8). ' 'https://doi.org/10.3390/pathogens11080823', 'DOI': '10.3390/pathogens11080823'}, { 'key': '268_CR30', 'doi-asserted-by': 'publisher', 'unstructured': 'Focosi D, McConnell S, Sullivan DJ, Casadevall A (2023b) Analysis of ' 'SARS-CoV-2 mutations associated with resistance to therapeutic ' 'monoclonal antibodies that emerge after treatment. Drug Resist Updates ' '100991. https://doi.org/10.1016/j.drup.2023.100991', 'DOI': '10.1016/j.drup.2023.100991'}, { 'key': '268_CR31', 'unstructured': 'Francica J, Rosenthal K, Ren K, Flores DJ et al (2023) The SARS-CoV-2 ' 'monoclonal antibody AZD3152 potently neutralises historical and ' 'currently circulating variants. ECCMID. Copenhagen'}, { 'key': '268_CR32', 'doi-asserted-by': 'publisher', 'unstructured': 'Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J et al (2021) ' 'Effect of bamlanivimab as monotherapy or in combination with etesevimab ' 'on viral load in patients with mild to moderate COVID-19: a randomized ' 'clinical trial. JAMA 325(7):632–644. ' 'https://doi.org/10.1001/jama.2021.0202%JJAMA', 'DOI': '10.1001/jama.2021.0202%JJAMA'}, { 'key': '268_CR42', 'doi-asserted-by': 'crossref', 'unstructured': 'Group RC, Horby PW, Mafham M, Peto L, Campbell M, Pessoa-Amorim G et al ' '(2022) Casirivimab and imdevimab in patients admitted to hospital with ' 'COVID-19 (RECOVERY): a randomised, controlled, open-label, platform ' 'trial. Lancet 399(10325):665–676. ' 'https://doi.org/10.1016/S0140-6736(22)00163-5', 'DOI': '10.1016/S0140-6736(22)00163-5'}, { 'key': '268_CR33', 'doi-asserted-by': 'publisher', 'unstructured': 'Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR et ' 'al (2021) Early treatment for Covid-19 with SARS-CoV-2 neutralizing ' 'antibody sotrovimab. N Engl J Med 385:1941–1950. ' 'https://doi.org/10.1056/NEJMoa2107934', 'DOI': '10.1056/NEJMoa2107934'}, { 'issue': '10', 'key': '268_CR34', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.ppat.1009542', 'volume': '17', 'author': 'K Haga', 'year': '2021', 'unstructured': 'Haga K, Takai-Todaka R, Matsumura Y, Song C, Takano T, Tojo T et al ' '(2021) Nasal delivery of single-domain antibody improves symptoms of ' 'SARS-CoV-2 infection in an animal model. PLoS Pathog 17(10):e1009542. ' 'https://doi.org/10.1371/journal.ppat.1009542', 'journal-title': 'PLoS Pathog'}, { 'key': '268_CR35', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ve/veac104', 'author': 'PJ Halfmann', 'year': '2022', 'unstructured': 'Halfmann PJ, Minor NR, Haddock LA III, Maddox R, Moreno GK, Braun KM et ' 'al (2022) Evolution of a globally unique SARS-CoV-2 Spike E484T ' 'monoclonal antibody escape mutation in a persistently infected, ' 'immunocompromised individual. Virus Evol. ' 'https://doi.org/10.1093/ve/veac104', 'journal-title': 'Virus Evol'}, { 'issue': '6428', 'key': '268_CR36', 'doi-asserted-by': 'publisher', 'first-page': '446', 'DOI': '10.1038/363446a0', 'volume': '363', 'author': 'C Hamers-Casterman', 'year': '1993', 'unstructured': 'Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, ' 'Songa EB et al (1993) Naturally occurring antibodies devoid of light ' 'chains. Nature 363(6428):446–448. https://doi.org/10.1038/363446a0', 'journal-title': 'Nature'}, { 'key': '268_CR37', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.virs.2023.07.003', 'author': 'Q Han', 'year': '2023', 'unstructured': 'Han Q, Wang S, Wang Z, Zhang C, Wang X, Feng N et al (2023) Nanobodies ' 'with cross-neutralizing activity provide prominent therapeutic efficacy ' 'in mild and severe COVID-19 rodent models. Virologica Sinica. ' 'https://doi.org/10.1016/j.virs.2023.07.003', 'journal-title': 'Virologica Sinica'}, { 'issue': '2', 'key': '268_CR38', 'doi-asserted-by': 'crossref', 'first-page': '530', 'DOI': '10.3390/v15020530', 'volume': '15', 'author': 'L Hao', 'year': '2023', 'unstructured': 'Hao L, Hsiang T-Y, Dalmat RR, Ireton R, Morton JF, Stokes C et al (2023) ' 'Dynamics of SARS-CoV-2 VOC neutralization and novel mAb reveal ' 'protection against Omicron. Viruses 15(2):530', 'journal-title': 'Viruses'}, { 'key': '268_CR39', 'doi-asserted-by': 'crossref', 'unstructured': 'Harman K, Nash SG, Webster HH, Groves N, Hardstaff J, Bridgen J et al ' '(2022) Comparison of the risk of hospitalisation among BA.1 and BA.2 ' 'COVID-19 cases treated with Sotrovimab in the community in England. ' 'Influenza Other Respi Viruses 17(5):e13150. ' 'https://doi.org/10.1111/irv.13150', 'DOI': '10.1111/irv.13150'}, { 'issue': '2', 'key': '268_CR40', 'doi-asserted-by': 'publisher', 'first-page': '250', 'DOI': '10.1067/mai.2001.116576', 'volume': '108', 'author': 'TK Hart', 'year': '2001', 'unstructured': 'Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE ' 'et al (2001) Preclinical efficacy and safety of mepolizumab (SB-240563), ' 'a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J ' 'Allergy Clin Immunol 108(2):250–257. ' 'https://doi.org/10.1067/mai.2001.116576', 'journal-title': 'J Allergy Clin Immunol'}, { 'key': '268_CR41', 'doi-asserted-by': 'publisher', 'unstructured': 'He Q, Wu L, Xu Z, Wang X, Xie Y, Chai Y et al (2023) An updated atlas of ' 'antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and ' 'XBB. Cell Rep Med 4(4):100991. ' 'https://doi.org/10.1016/j.xcrm.2023.100991', 'DOI': '10.1016/j.xcrm.2023.100991'}, { 'key': '268_CR43', 'doi-asserted-by': 'crossref', 'unstructured': 'Hurlburt NK, Homad LJ, Sinha I, Jennewein MF, MacCamy AJ, Wan Y-H et al ' '(2021) Structural definition of a pan-sarbecovirus neutralizing epitope ' 'on the spike S2 subunit. Commun Biol. ' 'https://doi.org/10.1038/s42003-022-03262-7', 'DOI': '10.1101/2021.08.02.454829'}, { 'key': '268_CR44', 'unstructured': 'IDSA Guidelines on the Treatment and Management of Patients with ' 'COVID-19 (2022). Accessed online at ' 'https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ ' 'on 9 Feb 2022'}, { 'issue': '7906', 'key': '268_CR45', 'doi-asserted-by': 'publisher', 'first-page': '553', 'DOI': '10.1038/s41586-022-04594-4', 'volume': '604', 'author': 'S Iketani', 'year': '2022', 'unstructured': 'Iketani S, Liu L, Guo Y, Liu L, Huang Y, Wang M et al (2022) Antibody ' 'evasion properties of SARS-CoV-2 Omicron sublineages. Nature ' '604(7906):553–556. https://doi.org/10.1038/s41586-022-04594-4', 'journal-title': 'Nature'}, { 'key': '268_CR46', 'doi-asserted-by': 'publisher', 'unstructured': 'Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S et al (2022) ' 'Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. ' 'N Engl J Med. https://doi.org/10.1056/NEJMc2214302', 'DOI': '10.1056/NEJMc2214302'}, { 'key': '268_CR47', 'doi-asserted-by': 'crossref', 'unstructured': 'Isa F, Forleo-Neto E, Meyer J, Zheng W, Rasmussen S, Armas D et al ' '(2021) Repeat subcutaneous administration of REGEN-COV® in adults is ' 'well-tolerated and prevents the occurrence of COVID-19. Int J Infect ' 'Dis. https://doi.org/10.1016/j.ijid.2022.06.045', 'DOI': '10.1016/j.ijid.2022.06.045'}, { 'key': '268_CR48', 'doi-asserted-by': 'publisher', 'unstructured': 'Ison MG, Weinstein DF, Dobryanska M, Holmes A, Phelan A-M, Li Y et al ' '(2023) Prevention of COVID-19 following a single intramuscular ' 'administration of Adintrevimab: results from a phase 2/3 randomized, ' 'double-blind, placebo-controlled trial (EVADE). Open Forum Infect Dis ' '10(7). https://doi.org/10.1093/ofid/ofad314', 'DOI': '10.1093/ofid/ofad314'}, { 'key': '268_CR49', 'doi-asserted-by': 'publisher', 'unstructured': 'Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, ' 'Delos Reyes V et al (2022) Molnupiravir for oral treatment of Covid-19 ' 'in nonhospitalized patients. N Engl J Med 386(6):509–520. ' 'https://doi.org/10.1056/NEJMoa2116044', 'DOI': '10.1056/NEJMoa2116044'}, { 'key': '268_CR50', 'doi-asserted-by': 'crossref', 'unstructured': 'Kaku Y, Okumura K, Padilla-Blanco M, Kosugi Y, Uriu K, Alfredo Amolong ' 'Hinay J et al (2023) Virological characteristics of the SARS-CoV-2 JN.1 ' 'variant. Lancet Infect Dis. ' 'https://doi.org/10.1016/S1473-3099(23)00813-7', 'DOI': '10.1101/2023.12.08.570782'}, { 'key': '268_CR51', 'doi-asserted-by': 'publisher', 'unstructured': 'Kaplon H, Chenoweth A, Crescioli S, Reichert JM (2022) Antibodies to ' 'watch in 2022. mAbs 14(1):2014296. ' 'https://doi.org/10.1080/19420862.2021.2014296', 'DOI': '10.1080/19420862.2021.2014296'}, { 'key': '268_CR52', 'doi-asserted-by': 'publisher', 'unstructured': 'Ku Z, Xie X, Lin J, Gao P, Sahili AE, Su H et al (2022) Engineering ' 'SARS-CoV-2 cocktail antibodies into a bispecific format improves ' 'neutralizing potency and breadth. medRxiv. ' 'https://doi.org/10.1101/2022.02.01.478504', 'DOI': '10.1101/2022.02.01.478504'}, { 'key': '268_CR53', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2116620', 'author': 'MJ Levin', 'year': '2022', 'unstructured': 'Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A et al ' '(2022) Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of ' 'Covid-19. N Engl J Med. https://doi.org/10.1056/NEJMoa2116620', 'journal-title': 'N Engl J Med'}, { 'key': '268_CR54', 'doi-asserted-by': 'crossref', 'unstructured': 'Li C, Zhan W, Yang Z, Tu C, Zhu Y, Song W et al (2021) Broad ' 'neutralization of SARS-CoV-2 variants by an inhalable bispecific ' 'single-domain antibody. Cell. https://doi.org/10.1016/j.cell.2022.03.009', 'DOI': '10.1101/2021.12.30.474535'}, { 'issue': '3', 'key': '268_CR55', 'doi-asserted-by': 'publisher', 'first-page': 'e336', 'DOI': '10.1093/cid/ciac448', 'volume': '76', 'author': 'Y Lin', 'year': '2023', 'unstructured': 'Lin Y, Yue S, Yang Y, Yang S, Pan Z, Yang X et al (2023) Nasal spray of ' 'neutralizing monoclonal antibody 35B5 confers potential prophylaxis ' 'against severe acute respiratory syndrome coronavirus 2 variants of ' 'concern: a small-scale clinical trial. Clin Infect Dis 76(3):e336–e341. ' 'https://doi.org/10.1093/cid/ciac448', 'journal-title': 'Clin Infect Dis'}, { 'key': '268_CR56', 'doi-asserted-by': 'crossref', 'unstructured': 'Liu Y, Zeng Q, Deng C, Li M, Li L, Liu D et al (2021) Robust induction ' 'of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 ' 'vaccine. Cell Discov. https://doi.org/10.1038/s41421-022-00373-7', 'DOI': '10.1101/2021.09.12.21263373'}, { 'key': '268_CR57', 'doi-asserted-by': 'publisher', 'first-page': '35', 'DOI': '10.1016/j.prrv.2018.12.001', 'volume': '33', 'author': 'MS Luna', 'year': '2020', 'unstructured': 'Luna MS, Manzoni P, Paes B, Baraldi E, Cossey V, Kugelman A et al (2020) ' 'Expert consensus on palivizumab use for respiratory syncytial virus in ' 'developed countries. Paediatr Respir Rev 33:35–44. ' 'https://doi.org/10.1016/j.prrv.2018.12.001', 'journal-title': 'Paediatr Respir Rev'}, { 'issue': '10', 'key': '268_CR58', 'doi-asserted-by': 'publisher', 'first-page': '905', 'DOI': '10.1056/NEJMoa2033130', 'volume': '384', 'author': 'JD Lundgren', 'year': '2021', 'unstructured': 'Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky ' 'U et al (2021) A neutralizing monoclonal antibody for hospitalized ' 'patients with Covid-19. N Engl J Med 384(10):905–914. ' 'https://doi.org/10.1056/NEJMoa2033130', 'journal-title': 'N Engl J Med'}, { 'key': '268_CR59', 'doi-asserted-by': 'publisher', 'unstructured': 'Martinez DR, Schäfer A, Gobeil S, Li D, De la Cruz G, Parks R et al ' '(2022) A broadly cross-reactive antibody neutralizes and protects ' 'against sarbecovirus challenge in mice. Sci Transl Med 14(629):eabj7125. ' 'https://doi.org/10.1126/scitranslmed.abj7125', 'DOI': '10.1126/scitranslmed.abj7125'}, { 'key': '268_CR60', 'doi-asserted-by': 'crossref', 'unstructured': 'McSweeney MD, Stewart I, Richardson Z, Kang H, Park Y, Kim C et al ' '(2022) Stable nebulization and muco-trapping properties of ' 'Regdanvimab/IN-006 support its development as a potent, dose-saving ' 'inhaled therapy for COVID-19. Bioeng Transl Med. ' 'http://doi.org/10.1002/btm2.10391', 'DOI': '10.1101/2022.02.27.482162'}, { 'issue': '9', 'key': '268_CR61', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.ppat.1009958', 'volume': '17', 'author': 'N Mishra', 'year': '2021', 'unstructured': 'Mishra N, Kumar S, Singh S, Bansal T, Jain N, Saluja S et al (2021) ' 'Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly ' 'neutralizing antibodies and polyclonal plasma. PLoS Pathog ' '17(9):e1009958. https://doi.org/10.1371/journal.ppat.1009958', 'journal-title': 'PLoS Pathog'}, { 'issue': '4', 'key': '268_CR62', 'doi-asserted-by': 'publisher', 'first-page': '230', 'DOI': '10.1016/s0968-0004(01)01790-x', 'volume': '26', 'author': 'S Muyldermans', 'year': '2001', 'unstructured': 'Muyldermans S, Cambillau C, Wyns L (2001) Recognition of antigens by ' 'single-domain antibody fragments: the superfluous luxury of paired ' 'domains. Trends Biochem Sci 26(4):230–235. ' 'https://doi.org/10.1016/s0968-0004(01)01790-x', 'journal-title': 'Trends Biochem Sci'}, { 'key': '268_CR63', 'doi-asserted-by': 'publisher', 'unstructured': 'Nambulli S, Xiang Y, Tilston-Lunel NL, Rennick LJ, Sang Z, Klimstra WB ' 'et al (2021) Inhalable nanobody (PiN-21) prevents and treats SARS-CoV-2 ' 'infections in Syrian hamsters at ultra-low doses. Sci Adv 7(22). ' 'https://doi.org/10.1126/sciadv.abh0319', 'DOI': '10.1126/sciadv.abh0319'}, { 'issue': '2', 'key': '268_CR64', 'doi-asserted-by': 'publisher', 'first-page': '164', 'DOI': '10.1006/clim.2000.4975', 'volume': '98', 'author': 'R Newman', 'year': '2001', 'unstructured': 'Newman R, Hariharan K, Reff M, Anderson DR, Braslawsky G, Santoro D et ' 'al (2001) Modification of the Fc region of a primatized IgG antibody to ' 'human CD4 retains its ability to modulate CD4 receptors but does not ' 'deplete CD4+ T cells in chimpanzees. Clin Immunol 98(2):164–174. ' 'https://doi.org/10.1006/clim.2000.4975', 'journal-title': 'Clin Immunol'}, { 'key': '268_CR65', 'doi-asserted-by': 'publisher', 'first-page': '1184', 'DOI': '10.1056/NEJMoa2109682', 'volume': '385', 'author': 'MP O’Brien', 'year': '2021', 'unstructured': 'O’Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan K-C, Sarkar N et al ' '(2021) Subcutaneous REGEN-COV antibody combination to prevent Covid-19. ' 'N Engl J Med 385:1184–1195. https://doi.org/10.1056/NEJMoa2109682', 'journal-title': 'N Engl J Med'}, { 'key': '268_CR66', 'doi-asserted-by': 'publisher', 'unstructured': 'Ohashi H, Hishiki T, Akazawa D, Kim KS, Woo J, Shionoya K et al (2022) ' 'Different efficacies of neutralizing antibodies and antiviral drugs on ' 'SARS-CoV-2 Omicron subvariants, BA.1 and BA.2. Antiviral Res. ' 'https://doi.org/10.1016/j.antiviral.2022.105372', 'DOI': '10.1016/j.antiviral.2022.105372'}, { 'issue': '6579', 'key': '268_CR67', 'doi-asserted-by': 'publisher', 'first-page': '449', 'DOI': '10.1126/science.abm8143', 'volume': '375', 'author': 'YJ Park', 'year': '2022', 'unstructured': 'Park YJ, De Marco A, Starr TN, Liu Z, Pinto D, Walls AC et al (2022) ' 'Antibody-mediated broad sarbecovirus neutralization through ACE2 ' 'molecular mimicry. Science 375(6579):449–454. ' 'https://doi.org/10.1126/science.abm8143', 'journal-title': 'Science'}, { 'key': '268_CR68', 'doi-asserted-by': 'publisher', 'unstructured': 'Patel V, Levick B, Boult S, Gibbons DC, Drysdale M, Lloyd EJ et al ' '(2023) Characteristics and outcomes of COVID-19 patients presumed to be ' 'treated with sotrovimab in NHS hospitals in England. medRxiv. ' 'https://doi.org/10.1101/2023.02.08.23285654', 'DOI': '10.1101/2023.02.08.23285654'}, { 'issue': '1', 'key': '268_CR69', 'doi-asserted-by': 'publisher', 'first-page': '77', 'DOI': '10.1016/0022-1759(94)00275-2', 'volume': '179', 'author': 'RS Peebles Jr', 'year': '1995', 'unstructured': 'Peebles RS Jr, Liu MC, Lichtenstein LM, Hamilton RG (1995) IgA, IgG and ' 'IgM quantification in bronchoalveolar lavage fluids from allergic ' 'rhinitics, allergic asthmatics, and normal subjects by monoclonal ' 'antibody-based immunoenzymetric assays. J Immunol Methods 179(1):77–86. ' 'https://doi.org/10.1016/0022-1759(94)00275-2', 'journal-title': 'J Immunol Methods'}, { 'key': '268_CR70', 'doi-asserted-by': 'publisher', 'unstructured': 'Piepenbrink MS, Park J-G, Deshpande A, Loos A, Ye C, Basu M et al (2022) ' 'Potent universal-coronavirus therapeutic activity mediated by direct ' 'respiratory administration of a Spike S2 domain-specific human ' 'neutralizing monoclonal antibody. bioRxiv. ' 'https://doi.org/10.1101/2022.03.05.483133', 'DOI': '10.1101/2022.03.05.483133'}, { 'issue': '6559', 'key': '268_CR71', 'doi-asserted-by': 'publisher', 'first-page': '1109', 'DOI': '10.1126/science.abj3321', 'volume': '373', 'author': 'D Pinto', 'year': '2021', 'unstructured': 'Pinto D, Sauer MM, Czudnochowski N, Low JS, Tortorici MA, Housley MP et ' 'al (2021) Broad betacoronavirus neutralization by a stem helix-specific ' 'human antibody. Science 373(6559):1109–1116. ' 'https://doi.org/10.1126/science.abj3321', 'journal-title': 'Science'}, { 'key': '268_CR72', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.annonc.2021.07.015', 'author': 'F Pommeret', 'year': '2021', 'unstructured': 'Pommeret F, Colomba J, Bigenwald C, Laparra A, Bockel S, Bayle A et al ' '(2021) Bamlanivimab+ etesevimab therapy induces SARS-CoV-2 immune escape ' 'mutations and secondary clinical deterioration in COVID-19 patients with ' 'B-cell malignancies. Ann Oncol. ' 'https://doi.org/10.1016/j.annonc.2021.07.015', 'journal-title': 'Ann Oncol'}, { 'key': '268_CR73', 'doi-asserted-by': 'crossref', 'unstructured': 'Qu P, Xu K, Faraone JN, Goodarzi N, Zheng Y-M, Carlin C et al (2023) ' 'Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 Omicron ' 'BA.2.86 and FLip variants. Cell. ' 'https://doi.org/10.1016/j.cell.2023.12.026', 'DOI': '10.1101/2023.09.11.557206'}, { 'key': '268_CR74', 'doi-asserted-by': 'publisher', 'unstructured': 'Qu P, Faraone JN, Evans JP, Zheng YM, Carlin C, Anghelina M et al (2023) ' 'Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, ' 'CH.1.1, and CA.3.1 variants. Cell Rep 42(5):112443. ' 'https://doi.org/10.1016/j.celrep.2023.112443', 'DOI': '10.1016/j.celrep.2023.112443'}, { 'issue': '11', 'key': '268_CR75', 'doi-asserted-by': 'publisher', 'first-page': '815', 'DOI': '10.1016/j.tips.2020.07.004', 'volume': '41', 'author': 'A Renn', 'year': '2020', 'unstructured': 'Renn A, Fu Y, Hu X, Hall MD, Simeonov A (2020) Fruitful neutralizing ' 'antibody pipeline brings hope to defeat SARS-Cov-2. Trends Pharmacol Sci ' '41(11):815–829. https://doi.org/10.1016/j.tips.2020.07.004', 'journal-title': 'Trends Pharmacol Sci'}, { 'key': '268_CR76', 'unstructured': 'Reuters (2022) GSK-Vir therapy has neutralising activity against Omicron ' 'sub-variant, data shows. Accessed online at ' 'https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-vir-therapy-works-against-omicron-sub-variant-data-suggests-2022-02-10/ ' 'on 15 Feb 2022'}, { 'issue': '12', 'key': '268_CR77', 'doi-asserted-by': 'publisher', 'first-page': '6147', 'DOI': '10.1128/aac.01285-13', 'volume': '57', 'author': 'GJ Robbie', 'year': '2013', 'unstructured': 'Robbie GJ, Criste R, Dall’acqua WF, Jensen K, Patel NK, Losonsky GA et ' 'al (2013) A novel investigational Fc-modified humanized monoclonal ' 'antibody, motavizumab-YTE, has an extended half-life in healthy adults. ' 'Antimicrob Agents Chemother 57(12):6147–6153. ' 'https://doi.org/10.1128/aac.01285-13', 'journal-title': 'Antimicrob Agents Chemother'}, { 'key': '268_CR78', 'doi-asserted-by': 'publisher', 'unstructured': 'Sabin AP, Richmond CS, Kenny PA (2022) Emergence and onward transmission ' 'of a SARS-CoV-2 E484K variant among household contacts of a ' 'bamlanivimab-treated patient. Diagn Microbiol Infect Dis 103(1):115656. ' 'https://doi.org/10.1101/2021.10.02.21264415%JmedRxiv', 'DOI': '10.1101/2021.10.02.21264415%JmedRxiv'}, { 'key': '268_CR79', 'doi-asserted-by': 'publisher', 'unstructured': 'Sanderson T, Hisner R, Donovan-Banfield I, Peacock T, Ruis C (2023) A ' 'molnupiravir-associated mutational signature in global SARS-CoV-2 ' 'genomes. Nature. https://doi.org/10.1038/s41586-023-06649-6', 'DOI': '10.1038/s41586-023-06649-6'}, { 'key': '268_CR80', 'doi-asserted-by': 'publisher', 'unstructured': 'Saunders KO (2019) Conceptual approaches to modulating antibody effector ' 'functions and circulation half-life. Front Immunol 10. ' 'https://doi.org/10.3389/fimmu.2019.01296', 'DOI': '10.3389/fimmu.2019.01296'}, { 'key': '268_CR81', 'doi-asserted-by': 'publisher', 'unstructured': 'Schäfer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S et ' 'al (2020) Antibody potency, effector function, and combinations in ' 'protection and therapy for SARS-CoV-2 infection in vivoIn vivo efficacy ' 'of anti–SARS-CoV-2 antibodies. J Exp Med 218(3). ' 'https://doi.org/10.1084/jem.20201993', 'DOI': '10.1084/jem.20201993'}, { 'issue': '10', 'key': '268_CR82', 'doi-asserted-by': 'publisher', 'first-page': '457', 'DOI': '10.1093/protein/gzw040', 'volume': '29', 'author': 'T Schlothauer', 'year': '2016', 'unstructured': 'Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick ' 'C et al (2016) Novel human IgG1 and IgG4 Fc-engineered antibodies with ' 'completely abolished immune effector functions. Protein Eng Des Select ' 'PEDS 29(10):457–466. https://doi.org/10.1093/protein/gzw040', 'journal-title': 'Protein Eng Des Select PEDS'}, { 'issue': '5', 'key': '268_CR83', 'doi-asserted-by': 'publisher', 'first-page': '622', 'DOI': '10.1016/S1473-3099(21)00751-9', 'volume': '22', 'author': 'WH Self', 'year': '2022', 'unstructured': 'Self WH, Sandkovsky U, Reilly CS, Vock DM, Gottlieb RL, Mack M et al ' '(2022) Efficacy and safety of two neutralising monoclonal antibody ' 'therapies, sotrovimab and BRII-196 plus BRII-198, for adults ' 'hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet ' 'Infect Dis 22(5):622–635. https://doi.org/10.1016/S1473-3099(21)00751-9', 'journal-title': 'Lancet Infect Dis'}, { 'key': '268_CR84', 'doi-asserted-by': 'publisher', 'unstructured': 'Sheward DJ, Yang Y, Westerberg M, Öling S, Muschiol S, Sato K et al ' '(2023) Sensitivity of BA.2.86 to prevailing neutralising antibody ' 'responses. Lancet Infect Dis. https://doi.org/10.1101/2023.09.02.556033', 'DOI': '10.1101/2023.09.02.556033'}, { 'key': '268_CR85', 'doi-asserted-by': 'publisher', 'unstructured': 'Shrestha LB, Tedla N, Bull RA (2021) Broadly-neutralizing antibodies ' 'against emerging SARS-CoV-2 variants. Front Immunol 12:752003. ' 'https://doi.org/10.3389/fimmu.2021.752003', 'DOI': '10.3389/fimmu.2021.752003'}, { 'key': '268_CR86', 'unstructured': 'Some States Still Pushing Ineffective Covid Antibody Treatments (2022). ' 'Accessed online at https://www.medscape.com/viewarticle/967020. Accessed ' 'on 26 April 2022'}, { 'key': '268_CR87', 'doi-asserted-by': 'publisher', 'unstructured': 'Song R, Zeng G, Yu J, Meng X, Chen X, Li J et al (2023) Post-exposure ' 'prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray ' 'for the prevention of symptomatic COVID-19 in healthy adult workers: a ' 'randomized, single-blind, placebo-controlled clinical study. Emerg ' 'Microbes Infect 2212806. https://doi.org/10.1080/22221751.2023.2212806', 'DOI': '10.1080/22221751.2023.2212806'}, { 'key': '268_CR88', 'doi-asserted-by': 'crossref', 'unstructured': 'Stadler E, Chai KL, Schlub TE, Cromer D, Polizzotto MN, Kent SJ et al ' '(2022a) Determinants of passive antibody efficacy in SARS-CoV-2 ' 'infection. Lancet Microbe. https://doi.org/10.1016/S2666-5247(23)00194-5', 'DOI': '10.1101/2022.03.21.22272672'}, { 'key': '268_CR89', 'doi-asserted-by': 'crossref', 'unstructured': 'Stadler E, Burgess MT, Schlub TE, Chai KL, McQuilten ZK, Wood EM et al ' '(2022b) Monoclonal antibody levels and protection from COVID-19. Nat ' 'Commun. https://doi.org/10.1038/s41467-023-40204-1', 'DOI': '10.1101/2022.11.22.22282199'}, { 'issue': '1', 'key': '268_CR90', 'doi-asserted-by': 'publisher', 'first-page': '6478', 'DOI': '10.1038/s41467-022-33864-y', 'volume': '13', 'author': 'DJ Sullivan', 'year': '2022', 'unstructured': 'Sullivan DJ, Franchini M, Joyner MJ, Casadevall A, Focosi D (2022) ' 'Analysis of anti-Omicron neutralizing antibody titers in different ' 'convalescent plasma sources. Nat Comm 13(1):6478. ' 'https://doi.org/10.1038/s41467-022-33864-y', 'journal-title': 'Nat Comm'}, { 'key': '268_CR91', 'doi-asserted-by': 'publisher', 'unstructured': 'Sullivan DJ, Franchini M, Senefeld JW, Joyner MJ, Casadevall A, Focosi D ' '(2023) Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 ' 'potently neutralizes BQ1.1 and XBB. J General Virol. ' 'https://doi.org/10.1101/2022.11.25.517977', 'DOI': '10.1101/2022.11.25.517977'}, { 'issue': '18', 'key': '268_CR92', 'doi-asserted-by': 'publisher', 'first-page': '2133', 'DOI': '10.1007/s40265-021-01626-7', 'volume': '81', 'author': 'YY Syed', 'year': '2021', 'unstructured': 'Syed YY (2021) Regdanvimab: first approval. Drugs 81(18):2133–2137. ' 'https://doi.org/10.1007/s40265-021-01626-7', 'journal-title': 'Drugs'}, { 'key': '268_CR93', 'doi-asserted-by': 'publisher', 'unstructured': 'Titong A, Gallolu Kankanamalage S, Dong J, Huang B, Spadoni N, Wang B et ' 'al (2022) First-in-class trispecific VHH-Fc based antibody with potent ' 'prophylactic and therapeutic efficacy against SARS-CoV-2 and variants. ' 'Sci Rep 12(1):4163. https://doi.org/10.1038/s41598-022-07952-4', 'DOI': '10.1038/s41598-022-07952-4'}, { 'issue': '7874', 'key': '268_CR94', 'doi-asserted-by': 'publisher', 'first-page': '103', 'DOI': '10.1038/s41586-021-03817-4', 'volume': '597', 'author': 'MA Tortorici', 'year': '2021', 'unstructured': 'Tortorici MA, Czudnochowski N, Starr TN, Marzi R, Walls AC, Zatta F et ' 'al (2021) Broad sarbecovirus neutralization by a human monoclonal ' 'antibody. Nature 597(7874):103–108. ' 'https://doi.org/10.1038/s41586-021-03817-4', 'journal-title': 'Nature'}, { 'key': '268_CR95', 'doi-asserted-by': 'crossref', 'unstructured': 'Touret F, Giraud E, Bourret J, Donati F, Tran-Rajau J, Chiaravalli J et ' 'al (2022) Enhanced neutralization escape to therapeutic monoclonal ' 'antibodies by SARS-CoV-2 Omicron sub-lineages. iScience. ' 'https://doi.org/10.1016/j.isci.2023.106413', 'DOI': '10.1101/2022.12.22.521201'}, { 'key': '268_CR96', 'unstructured': 'Update on AZD7442 STORM CHASER trial in post-exposure prevention of ' 'symptomatic COVID-19 (2022). Accessed online at ' 'https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-azd7442-storm-chaser-trial.html ' 'on 21 Feb 2022'}, { 'key': '268_CR97', 'doi-asserted-by': 'publisher', 'unstructured': 'Uriu K, Ito J, Kosugi Y, Tanaka YL, Mugita Y, Guo Z et al (2023) ' 'Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 ' 'BA.2.86 variant. Lancet Infect Dis. ' 'https://doi.org/10.1016/S1473-3099(23)00575-3', 'DOI': '10.1016/S1473-3099(23)00575-3'}, { 'key': '268_CR98', 'unstructured': 'US Food and Drug Administration (FDA) (2021) Clinical memorandum Re: EUA ' '26382. Product: COVID-19 Convalescent Plasma. Issued on December 27, ' '2021 at https://www.fda.gov/media/141477/download'}, { 'key': '268_CR99', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2022.105252', 'volume': '198', 'author': 'L Vangeel', 'year': '2022', 'unstructured': 'Vangeel L, De Jonghe S, Maes P, Slechten B, Raymenants J, André E et al ' '(2022) Remdesivir, Molnupiravir and Nirmatrelvir remain active against ' 'SARS-CoV-2 Omicron and other variants of concern. Antiviral Res ' '198:105252. https://doi.org/10.1016/j.antiviral.2022.105252', 'journal-title': 'Antiviral Res'}, { 'issue': '5', 'key': '268_CR100', 'doi-asserted-by': 'publisher', 'first-page': 'e162', 'DOI': '10.1016/j.jinf.2022.07.014', 'volume': '85', 'author': 'C Vellas', 'year': '2022', 'unstructured': 'Vellas C, Kamar N, Izopet J (2022) Resistance mutations in SARS-CoV-2 ' 'Omicron variant after tixagevimab-cilgavimab treatment. J Infect ' '85(5):e162–e163. https://doi.org/10.1016/j.jinf.2022.07.014', 'journal-title': 'J Infect'}, { 'issue': '2', 'key': '268_CR101', 'doi-asserted-by': 'publisher', 'first-page': '279', 'DOI': '10.1016/j.cell.2022.12.018', 'volume': '186', 'author': 'Q Wang', 'year': '2023', 'unstructured': 'Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y et al (2023b) Alarming ' 'antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. ' 'Cell 186(2):279–86.e8. https://doi.org/10.1016/j.cell.2022.12.018', 'journal-title': 'Cell'}, { 'key': '268_CR102', 'doi-asserted-by': 'publisher', 'unstructured': 'Wang X, Jiang S, Jiang S, Li X, Ai J, Lin K et al (2023a) Neutralization ' 'of SARS-CoV-2 BQ.1.1 and XBB.1.5 by breakthrough infection sera from ' 'previous and current waves in China. bioRxiv. ' 'https://doi.org/10.1101/2023.02.07.527406', 'DOI': '10.1101/2023.02.07.527406'}, { 'key': '268_CR103', 'doi-asserted-by': 'publisher', 'unstructured': 'Wang Q, Guo Y, Zhang RM, Ho J, Mohri H, Valdez R et al. (2023c) Antibody ' 'neutralization of emerging SARS-CoV-2: EG.5.1 and XBC.1.6. bioRxiv. ' 'https://doi.org/10.1101/2023.08.21.553968', 'DOI': '10.1101/2023.08.21.553968'}, { 'key': '268_CR104', 'volume-title': 'Trial in progress: a Phase I/III, randomised, modified double-blind, ' 'placebo- and active-controlled pre-exposure prophylaxis study of the ' 'SARS-CoV-2–neutralising antibody AZD3152 (SUPERNOVA)', 'author': 'C Webber', 'year': '2023', 'unstructured': 'Webber C, Beavon R, Thomas S, Chang LA, Cohen T, Perez J (2023) Trial in ' 'progress: a Phase I/III, randomised, modified double-blind, placebo- and ' 'active-controlled pre-exposure prophylaxis study of the ' 'SARS-CoV-2–neutralising antibody AZD3152 (SUPERNOVA). ECCMID, ' 'Copenhagen'}, { 'issue': '23', 'key': '268_CR105', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2108163', 'volume': '385', 'author': 'DM Weinreich', 'year': '2021', 'unstructured': 'Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R et al ' '(2021) REGEN-COV antibody combination and outcomes in outpatients with ' 'Covid-19. N Engl J Med 385(23):e81. ' 'https://doi.org/10.1056/NEJMoa2108163', 'journal-title': 'N Engl J Med'}, { 'issue': '9', 'key': '268_CR106', 'doi-asserted-by': 'publisher', 'first-page': '3952', 'DOI': '10.1172/jci128437', 'volume': '129', 'author': 'P Weitzenfeld', 'year': '2019', 'unstructured': 'Weitzenfeld P, Bournazos S, Ravetch JV (2019) Antibodies targeting ' 'sialyl Lewis A mediate tumor clearance through distinct effector ' 'pathways. J Clin Investig 129(9):3952–3962. ' 'https://doi.org/10.1172/jci128437', 'journal-title': 'J Clin Investig'}, { 'issue': '3', 'key': '268_CR107', 'doi-asserted-by': 'publisher', 'first-page': '652', 'DOI': '10.1016/j.jmb.2007.02.024', 'volume': '368', 'author': 'H Wu', 'year': '2007', 'unstructured': 'Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK et al (2007) ' 'Development of Motavizumab, an ultra-potent antibody for the prevention ' 'of respiratory syncytial virus infection in the upper and lower ' 'respiratory tract. J Mol Biol 368(3):652–665. ' 'https://doi.org/10.1016/j.jmb.2007.02.024', 'journal-title': 'J Mol Biol'}, { 'issue': '10369', 'key': '268_CR108', 'doi-asserted-by': 'publisher', 'first-page': '2193', 'DOI': '10.1016/s0140-6736(22)01938-9', 'volume': '400', 'author': 'MY Wu', 'year': '2022', 'unstructured': 'Wu MY, Carr EJ, Harvey R, Mears HV, Kjaer S, Townsley H et al (2022a) ' 'WHO’s therapeutics and COVID-19 living guideline on mAbs needs to be ' 'reassessed. Lancet 400(10369):2193–2196. ' 'https://doi.org/10.1016/s0140-6736(22)01938-9', 'journal-title': 'Lancet'}, { 'key': '268_CR109', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fimmu.2022.865401', 'volume': '13', 'author': 'X Wu', 'year': '2022', 'unstructured': 'Wu X, Wang Y, Cheng L, Ni F, Zhu L, Ma S et al (2022b) Short-term ' 'instantaneous prophylaxis and efficient treatment against SARS-CoV-2 in ' 'hACE2 mice conferred by an intranasal nanobody (Nb22). Front Immunol ' '13:865401. https://doi.org/10.3389/fimmu.2022.865401', 'journal-title': 'Front Immunol'}, { 'key': '268_CR110', 'doi-asserted-by': 'publisher', 'unstructured': 'Yamasoba D, Uriu K, Plianchaisuk A, Kosugi Y, Pan L, Zahradnik J et al ' '(2023) Virological characteristics of the SARS-CoV-2 Omicron XBB.1.16 ' 'variant. Lancet Infect Dis 23(6):655–656. ' 'https://doi.org/10.1016/S1473-3099(23)00278-5', 'DOI': '10.1016/S1473-3099(23)00278-5'}, { 'key': '268_CR111', 'doi-asserted-by': 'publisher', 'unstructured': 'Yang S, Yu Y, Jian F, Song W, Yisimayi A, Chen X et al (2023a) ' 'Antigenicity and infectivity characterization of SARS-CoV-2 BA.2.86. ' 'Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(23)00573-X', 'DOI': '10.1016/S1473-3099(23)00573-X'}, { 'key': '268_CR112', 'doi-asserted-by': 'publisher', 'unstructured': 'Yang S, Yu Y, Xu Y, Jian F, Song W, Yisimayi A et al (2023b) Fast ' 'evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. ' 'Lancet Infect Dis. https://doi.org/10.1101/2023.11.13.566860', 'DOI': '10.1101/2023.11.13.566860'}, { 'issue': '2', 'key': '268_CR113', 'doi-asserted-by': 'publisher', 'first-page': '157', 'DOI': '10.1038/nbt.1601', 'volume': '28', 'author': 'J Zalevsky', 'year': '2010', 'unstructured': 'Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, Sproule TJ et ' 'al (2010) Enhanced antibody half-life improves in vivo activity. Nat ' 'Biotechnol 28(2):157–159. https://doi.org/10.1038/nbt.1601', 'journal-title': 'Nat Biotechnol'}, { 'issue': '3', 'key': '268_CR114', 'doi-asserted-by': 'publisher', 'first-page': '415', 'DOI': '10.1093/infdis/jiab247', 'volume': '224', 'author': 'S Zhou', 'year': '2021', 'unstructured': 'Zhou S, Hill CS, Sarkar S, Tse LV, Woodburn BMD, Schinazi RF et al ' '(2021) β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal ' 'mutagenesis but is also mutagenic to mammalian cells. J Infect Dis ' '224(3):415–419. https://doi.org/10.1093/infdis/jiab247', 'journal-title': 'J Infect Dis'}, { 'key': '268_CR115', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhou H, Tada T, Dcosta BM, Landau NR (2022) SARS-CoV-2 Omicron BA.2 ' 'variant evades neutralization by therapeutic monoclonal antibodies. ' 'Viruses. https://doi.org/10.3390/v14061334', 'DOI': '10.3390/v14061334'}, { 'key': '268_CR116', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhou P, Song G, He W-t, Beutler N, Tse LV, Martinez DR et al (2022b) ' 'Broadly neutralizing anti-S2 antibodies protect against all three human ' 'betacoronaviruses that cause severe disease. Immunity. ' 'https://doi.org/10.1016/j.immuni.2023.02.005', 'DOI': '10.1016/j.immuni.2023.02.005'}, { 'key': '268_CR117', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhou P, Yuan M, Song G, Beutler N, Shaabani N, Huang D et al (2022c) A ' 'human antibody reveals a conserved site on beta-coronavirus spike ' 'proteins and confers protection against SARS-CoV-2 infection. Sci Transl ' 'Med. https://doi.org/10.1126/scitranslmed.abi9215', 'DOI': '10.1126/scitranslmed.abi9215'}], 'container-title': 'Current Topics in Microbiology and Immunology', 'original-title': [], 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/82_2024_268', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 8, 10]], 'date-time': '2024-08-10T13:04:29Z', 'timestamp': 1723295069000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/82_2024_268'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024]]}, 'references-count': 117, 'URL': 'http://dx.doi.org/10.1007/82_2024_268', 'relation': {}, 'ISSN': ['0070-217X', '2196-9965'], 'subject': [], 'published': {'date-parts': [[2024]]}, 'assertion': [ { 'value': '11 August 2024', 'order': 1, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ChapterHistory', 'label': 'Chapter History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit